DL-Mevalonolactone-d7

DL-Mevalonolactone-d7

• CAS Number: 347840-19-1
• UNSPSC Description: DL-Mevalonolactone-d7 is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (∆Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling[1][2].
• Target Antigen: Endogenous Metabolite
• Type: Isotope-Labeled Compounds
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Metabolism-protein/nucleotide metabolism
• Field of Research: Metabolic Disease
• Purity: 99.0
• Solubility: 10 mM in DMSO
• Smiles: OC1(CC(OC([2H])([2H])C1([2H])[2H])=O)C([2H])([2H])[2H]
• Molecular Weight: 137.18
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Domingos SR, et al. On the structural intricacies of a metabolic precursor: Direct spectroscopic detection of water-induced conformational reshaping of mevalonolactone. J Chem Phys. 2017 Sep 28;147(12):124310.|[3]Cecatto C, et al. Mevalonolactone disrupts mitochondrial functions and induces permeability transition pore opening in rat brain mitochondria: Implications for the pathogenesis of mevalonic aciduria. Neurochem Int. 2017 Sep;108:133-145.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported